Skip to main content

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.

Publication ,  Journal Article
Antonia, SJ
Published in: N Engl J Med
March 7, 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 7, 2019

Volume

380

Issue

10

Start / End Page

990

Location

United States

Related Subject Headings

  • Lung Neoplasms
  • Humans
  • General & Internal Medicine
  • Chemoradiotherapy
  • Carcinoma, Non-Small-Cell Lung
  • Antibodies, Monoclonal
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Antonia, S. J. (2019). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. N Engl J Med, 380(10), 990. https://doi.org/10.1056/NEJMc1900407
Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.N Engl J Med 380, no. 10 (March 7, 2019): 990. https://doi.org/10.1056/NEJMc1900407.
Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.N Engl J Med, vol. 380, no. 10, Mar. 2019, p. 990. Pubmed, doi:10.1056/NEJMc1900407.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 7, 2019

Volume

380

Issue

10

Start / End Page

990

Location

United States

Related Subject Headings

  • Lung Neoplasms
  • Humans
  • General & Internal Medicine
  • Chemoradiotherapy
  • Carcinoma, Non-Small-Cell Lung
  • Antibodies, Monoclonal
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences